Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Trading Update Meten International Education Group
-
Trading Update Meten International Education Group
-
Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Chardan Capital Markets Starts Homology Medicines (FIXX) at Buy
-
Axovant (AXGT) Prices 14.03M Share Common Offering at $3.75/Sh
-
Axovant Gene Therapies Announces Pricing of $65 Million Public Offering
-
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
-
Newborn Acquisition Corp. (NBAC) Prices 5M Unit IPO at $10/Unit
-
Newborn Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
Catalyst Biosciences (CBIO) Prices 4.6M Shares at $6.50
-
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
-
UPDATE: Moderna (MRNA) Prices 26.32M Share Common Offering at $19/Sh
-
Moderna Announces Pricing of Public Offering of Shares of Common Stock
-
UPDATE: Chardan Capital Markets Upgrades Adverum Biotechnologies (ADVM) to Buy
-
Applied Genetic Technologies Corp. (AGTC) PT Raised to $10 at Chardan Capital Markets
-
Esperion Therapeutics (ESPR) PT Raised to $65 at Chardan Capital Markets
-
Buy Regenxbio (RGNX) for Breakup Story - Chardan Capital Markets
-
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement
-
Chardan Capital Markets Reiterates Buy Rating on 4D Pharma Plc (DDDD:LN)
-
SPAC Research Releases League Tables Featuring Top SPAC Underwriters and Law Firms of 2019
-
Chardan Capital Markets Starts Immunovant (IMVT) at Buy; Named Top 2020 Pick
-
Exicure Announces the Closing of its Offering of Common Stock
-
Chardan Acts as M&A Advisor in Health Sciences Acquisitions Corporation Completed Merger with Immunovant
-
Exicure Inc. (XCUR) Prices 10M Share Common Offering at $2.75/Sh
-
Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock
-
Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $190 at Chardan Capital Markets
-
EdtechX Holdings (NASDAQ:EDTX) Announces Transaction With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Transaction With Meten Education (China)
-
EdtechX Holdings (EDTX) Announces Merger Agreement With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Merger Agreement With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Merger Agreement With Meten Education (China)
-
Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets
-
Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Chardan Capital Markets Downgrades Audentes Therapeutics (BOLD) to Neutral
-
Kodiak Sciences Inc. (KOD) Prices 6M Share Common Offering at $46/Sh
-
Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock
-
Chardan Capital Positive on Kodiak Sciences' (KOD) $225M Baker Bros. Royalty Deal
-
Arrowhead Research (ARWR) PT Raised to $81 at Chardan Capital Markets
-
Pre-Open Movers 11/27 (AVX) (MDR) (TNXP) Higher; (ARAV) (GES) (DELL) Lower (more...)
-
Ocugen (OCGN) Ramps 20%+ on New Buy Rating
-
Chardan Capital Markets Starts Ocugen, Inc. (OCGN) at Buy
-
Chardan Capital Markets Downgrades The Medicines Company (MDCO) to Neutral on Valuation, Removes as Top Pick
-
CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh
-
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
-
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
-
OncoCyte Provides Corporate Update and Reports Third Quarter 2019 Financial Results
-
Chardan Capital Markets Upgrades Vascular Biogenics Ltd (VBLT) to Buy
-
Stone Street Group Initiates Coverage On BiomX Inc.

